A bipartisan team of prominent members of both US houses of Congress have introduced the National Neurotechnology Initiative (NNTI) Act, a bill designed to foster novel discoveries and accelerate the development of new and safer treatments for the one in three Americans living with a brain-related illness, injury or disease.
Championing the NNTI, Senators Pete Domenici (Republican, New Mexico) and Patty Murray (Democrat, Washington State) and Representatives Patrick Kennedy (D-Rhode Island 1st) and Ileana Ros-Lehtinen (R-Florida 18th) have called upon Congress to reverse the growing economic burden generated by brain-related illness, which has reached $1,300.0 billion a year in the USA due to health care costs and lost income.
"The sheer numbers speak for themselves: There are 100 million Americans suffering from a brain-related illness, with an enormous economic burden that continues to grow as the population ages," said Zack Lynch, executive director of the Neurotechnology Industry Organization, commenting on the initiative. "For a modest investment, Congress has the opportunity to streamline research efforts, accelerate the development of new treatments, promote innovation by small businesses and have a meaningful impact on the lives of those suffering from devastating diseases and injuries," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze